(24/7 MARKET NEWS) – Baudax Bio, Inc. (NASDAQ: BXRX) stated, this morning, that U.S. Food and Drug Administration (FDA) granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors. TI-168 is the Company’s next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors.
Baudax Bio is trading at $0.46, up $0.16 (+52.00%), on 219.19K premarket shares traded.
Its 52-week range is $0.30 to $12.24. It just crossed a key inflection point and its next key inflection point is 59-cents. If it breaks through that, on strong trading volume, it looks like it has several manageable waves to retrace to as high as $1, but the volume needs to pick up for that to possibly happen.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.